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Summary
Background Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week 
period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and 
Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with 
type 2 diabetes.
Methods In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of 
at least 30 kg/m², or at least 27 kg/m² with comorbidities, were randomised 2:1, using a telephone or web-based 
system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and 
increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised 
treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 
27 countries and is registered with ClinicalTrials.gov, number NCT01272219.
Findings The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive 
liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal 
of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 
26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with 
diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 
26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the 
different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 
160 weeks among all randomised individuals was 2·7 times longer with liraglutide than with placebo (95% CI 
1·9 to 3·9, p<0·0001), corresponding with a hazard ratio of 0·21 (95% CI 0·13–0·34). Liraglutide induced greater 
weight loss than placebo at week 160 (–6·1 [SD 7·3] vs –1·9% [6·3]; estimated treatment difference –4·3%, 95% CI 
–4·9 to –3·7, p<0·0001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in 
the liraglutide group versus 96 (13%) of 747 individuals in the placebo group.
Interpretation In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals 
were not followed up after discontinuation. Liraglutide 3·0 mg might provide health benefits in terms of reduced risk 
of diabetes in individuals with obesity and prediabetes.
Funding Novo Nordisk, Denmark.
Introduction
Prediabetes and obesity are risk factors for type 2 diabetes 
mellitus1–3 and its complications.3 The prevalence of 
diabetes is increasing,1–3 and each year 5–10% of people 
with prediabetes develop diabetes.4 Weight loss through 
lifestyle intervention, with or without pharmacotherapy, 
can reduce the risk of developing diabetes.4–9
Once-daily subcutaneous liraglutide 3·0 mg, as an 
adjunct to a reduced-calorie diet and increased physical 
activity, is approved for weight management in several 
regions, including North America and Europe. Liraglutide 
promotes weight loss through reduced appetite and 
energy intake.10 The 56-week period of the current trial 
was reported previously11 and evaluated the efficacy and 
safety of liraglutide 3·0 mg for weight loss after 56 weeks. 
Liraglutide was associated with substantial weight loss in 
individuals with or without prediabetes who had obesity 
or overweight with comorbidities, and reduced type 2 
diabetes incidence. Individuals who had prediabetes at 
screening continued on treatment in the trial for a further 
two years, and are the subject of this report.
In this 3-year trial, we aimed to evaluate the effect of 
liraglutide 3·0 mg in terms of time of onset of type 2 
diabetes in individuals with prediabetes, as well as on 
weight loss and safety over 3 years.
Methods
SCALE Obesity and Prediabetes was conducted as part of 
a large global phase 3a clinical development programme 
of four randomised, double-blind, placebo-controlled 
trials with more than 5000 participants that was designed 
to investigate the efficacy and safety of liraglutide 3·0 mg, 
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a glucagon-like peptide-1 (GLP-1) receptor agonist, 
for weight management.11–14 We did this study at 
191 clinical research sites in 27 countries in Europe, 
North America, South America, Asia, Africa, and 
Australia (appendix p 9). The protocol was approved by 
local ethics committees or institutional review boards. We 
did the study according to the Declaration of Helsinki15 
and Good Clinical Practice.16 The 56-week period of the 
trial evaluated the efficacy and safety of liraglutide 3·0 mg 
for weight management in individuals with and without 
prediabetes.11 From week 56, individuals with prediabetes 
at screening continued on treatment for a further 2 years, 
with a 12-week off-treatment follow-up period.
Participants
We enrolled adults aged 18 years or older with stable 
bodyweight and a body-mass index (BMI) of at least 
30 kg/m², or at least 27 kg/m² with treated or untreated 
dyslipidaemia, or hypertension, or both. Key exclusion 
criteria were type 1 or type 2 diabetes, medications 
causing significant weight gain or loss, bariatric surgery, 
history of pancreatitis, major depressive or other severe 
psychiatric disorders, and family or personal history of 
multiple endocrine neoplasia type 2 or familial medullary 
thyroid carcinoma. Detailed eligibility and exclusion 
criteria are provided in the appendix p 31. Each individual 
provided written informed consent before participation.
Randomisation and masking
Participants were randomly assigned, in a 2:1 ratio, to 
receive liraglutide 3·0 mg or placebo. Randomisation was 
performed using a funder-provided telephone or web-
based system. The funder generated the random allocation 
sequence, and the trial investigators enrolled individuals, 
and assigned them to treatment. Participants were 
stratified at screening by BMI (≥30 kg/m² vs <30 kg/m²) 
and according to whether or not they had prediabetes. 
Those individuals who had prediabetes and completed 
56 weeks of treatment continued for an additional 
104 weeks of treatment, allowing for a total of 160 weeks of 
treatment. Participants without prediabetes were on 
treatment for 56 weeks, followed by a 12-week re-
randomised period; results for this period of the trial have 
been reported previously.11 We did not include participants 
without prediabetes in this trial, thus the stratification 
factor is not included in the statistical analysis. Participants 
and investigators were masked to treatment allocation 
during the entire trial (160 weeks plus the 12-week off-
treatment follow-up period) and visually identical devices 
were used for subcutaneous injection, whereas the funder 
was unmasked to treatment allocation at week 56.
Procedures
This report covers participants with prediabetes who were 
randomised to treatment for the full 3-year period. We 
diagnosed participants with prediabetes on the basis of 
fulfilment of at least one of the three American Diabetes 
Association (ADA) 2010 criteria: 5·7−6·4% glycated 
haemoglobin, or fasting plasma glucose concentration 
between 5·6 mmol/L and 6·9 mmol/L, or 2-h post-
challenge plasma glucose concentration between 
7·8 mmol/L and 11·0 mmol/L.17 Diagnosis of diabetes was 
confirmed by two consecutive measurements of the same 
type of criteria: at least 6·5% glycated haemoglobin, or at 
least 7·0 mmol/L fasting plasma glucose concentration, 
or at least 11·1 mmol/L 2-h post-challenge plasma glucose 
concentration.17 Liraglutide and placebo were provided in 
prefilled FlexPen devices (Novo Nordisk, Bagsværd, 
Denmark), starting at 0·6 mg with weekly 0·6 mg 
incremental increases to 3·0 mg. All trial participants 
received standardised lifestyle intervention counselling 
from randomisation to end of follow-up, about once a 
month (appendix p 3). Participants were advised to achieve 
at least 150 minutes of physical activity per week and to 
Research in context
Evidence before this study
We searched PubMed from Jan 1, 1990, to April 30, 2016, using 
the terms “obesity”, and “liraglutide”, and “randomised clinical 
trial”. We found 45 articles assessing liraglutide treatment, 
including one phase 1 study, seven randomised controlled 
studies, and seven review articles that evaluated liraglutide at a 
dose of 3·0 mg for weight management. Of those articles, 
one randomised controlled study was performed in individuals 
with and without prediabetes over a 56-week treatment 
period. According to study design, individuals who had 
prediabetes at screening continued on treatment for a further 
two years, and are the subject of the current report.
Added value of this study
Few trials of anti-obesity medications have been done for a 
period of 3 years. This study provides clinically important 
long-term data on the efficacy and safety of liraglutide 3·0 mg 
in individuals with prediabetes treated for 3 years followed by a 
12-week off-treatment follow-up period. Treatment with 
liraglutide 3·0 mg for 3 years was associated with a reduced risk 
of type 2 diabetes, weight loss and improvements in glycaemic 
control in individuals with prediabetes. Liraglutide 3·0 mg was 
generally well tolerated and no new safety signals were 
observed as compared with the previous evaluation after 
56 weeks of treatment.
Implications of all the available evidence
Treatment with once-daily subcutaneous liraglutide 3·0 mg for 
3 years, combined with a reduced-calorie diet and increased 
physical activity, might not only provide a sustained clinically 
relevant weight loss, but also additional health benefits in 
terms of reduced risk of type 2 diabetes, as well as 
improvements in glycaemic control in a high-risk group of 
individuals with prediabetes and overweight or obesity.
See Online for appendix
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reduce their daily energy intake to 500 kcal below their 
individualised energy requirement. Additional method-
ology, including timing of assessments, is described in the 
appendix p 3.
Outcomes
Our primary objective was to evaluate the proportion of 
individuals with type 2 diabetes at 160 weeks, with time to 
onset of diabetes as the primary endpoint. The trial had 
four coprimary endpoints, three of which were assessed at 
week 56—mean weight loss, and the proportion of 
participants losing at least 5% of their baseline bodyweight, 
and more than 10% of their baseline bodyweight.11 
Secondary endpoints included changes from baseline to 
week 160 in glycaemic control parameters, mean and 
categorical bodyweight, BMI, waist circumference, 
cardiometabolic biomarkers, vital signs, and health-related 
quality of life—assessed using validated questionnaires.18–20
Specific adverse events with increased prevalence 
among people with obesity, or of relevance to the GLP-1 
drug class, were assessed (appendix p 33). Independent 
medical experts prospectively adjudicated nine of 17 event 
types in a blinded manner. We report adverse events that 
occurred during the 160-week trial period, from the first 
treatment day to 14 days after the last treatment day, 
unless otherwise stated.
Statistical analysis
A target sample size of 3600 randomised individuals, 
2400 to liraglutide 3·0 mg and 1200 to placebo, was 
chosen to provide an assessment of the safety and efficacy 
of liraglutide 3·0 mg for 3 years. This size provided 
enough power for the primary endpoint of the 3 year 
trial, the fourth coprimary endpoint, which was the long-
term efficacy of liraglutide 3·0 mg in delaying onset of 
diabetes in individuals with a diagnosis of prediabetes at 
screening. Superiority for liraglutide 3·0 mg versus 
placebo was tested in a hierarchical manner with respect 
to the four coprimary endpoints to control for multiple 
testing, whereby the second, third, and fourth endpoints 
were tested only if the previous endpoint had achieved 
statistical significance.
For the power estimation, a conservative approach was 
chosen using the binary endpoint type 2 diabetes “yes 
versus no” assessed in completers during the 160 weeks 
of treatment and analysed with a two-sided χ² test with a 
5% significance level.
We assumed that the annual conversion rate to type 2 
diabetes of the individuals with prediabetes would be 
7·0% in the placebo group and 2·1% in the liraglutide 
3·0 mg group—ie, 70% lower in the liraglutide 3·0 mg 
group. After 160 weeks of treatment, the percentage of 
individuals with diabetes was therefore estimated to be 
1–(1–0·07)³ or 20% among individuals in the placebo 
group, and 1–(1–0·021)³ or 6% among those in the 
liraglutide group. The dropout rate during the 160 weeks 
of treatment was assumed to be 65% in both groups.
Figure 1: Trial profile
AE=adverse event.*Individuals could be excluded for more than one criterion.  The 3-year trial population 
consisted of all individuals with prediabetes, except for those that were incorrectly stratified: 37 entered the re-
randomised period of the 56-week part of the trial, reported previously,11 and are not included, and six with 
normoglycaemia entered the 3-year part of the trial and are included. 
4992 assessed for eligibility
2254 randomised
1505 allocated to liraglutide 3·0 mg
1501 received liraglutide 3·0 mg
4 did not receive liraglutide 3·0 mg
714 withdrawn
191 adverse events
29 ineffective therapy
73 non-compliance
360 withdrawal criteria (including 8 AE 
withdrawals)
60 other
1 missing withdrawal reason
791 completed 160 weeks
Analysed
1472 full analysis set (33 excluded due to no exposure 
or no post-baseline values)
1501 safety analysis set
787 entered off-drug follow-up period
4 withdrawn
0 adverse events
0 ineffective therapy
2 non-compliance
2 withdrawal criteria
0 other
783 completed 172 weeks
Analysed
783 full analysis set
787 safety analysis set
749 allocated to placebo
747 received placebo
2 did not receive placebo
412 withdrawn
43 adverse events
36 ineffective therapy
34 non-compliance
249 withdrawal criteria (including 3 AE 
withdrawals)
50 other
0 missing withdrawal reason
337 completed 160 weeks
Analysed
738 full analysis set (11 excluded due to no exposure 
or no post-baseline values)
747 safety analysis set
336 entered off-drug follow-up period
9 withdrawn
0 adverse events
0 ineffective therapy
2 non-compliance
6 withdrawal criteria
1 other
327 completed 172 weeks
Analysed
326 full analysis set
336 safety analysis set
1477 individuals with normoglycaemia randomised 
in 56-week period of the trial and reported 
previously
982 liraglutide 3·0 mg
495 placebo
1261 excluded*
42 did not meet inclusion criteria
909 met exclusion criteria
338 other reasons
Analysis at 160 weeks
Analysis at 172 weeks
12-week off-drug follow-up period
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The prespecified efficacy analyses used data from the 
full-analysis set of all randomised individuals who 
received at least one treatment dose and had at least 
one post-baseline assessment. The safety-analysis set 
included all randomised individuals who received at 
least one treatment dose. We imputed missing values 
using last-observation-carried-forward for post-baseline 
measurements. The primary endpoint of the 3-year trial 
was analysed using a Weibull model, using methods for 
the analysis of interval-censored time-to-event data. 
The Weibull model included treatment, sex, and 
baseline BMI stratum as fixed-effects, and baseline 
fasting glucose value as a covariate. We analysed mean 
changes in continuous endpoints using an analysis of 
covariance and categorical changes for dichotomous 
endpoints with logistic regression. We did sensitivity 
analyses to assess the robustness of the primary 
analysis and the analyses for mean and categorical 
weight loss (appendix p 36).
The handling of missing data has progressed since the 
prespecified analyses were defined,21 therefore we 
specified additional post-hoc analyses to further address 
the issue. We did a post-hoc Cox regression analysis at 
week 172, in which we imputed diabetes status for all 
withdrawn individuals. We firstly assumed that 1% of 
withdrawn individuals in the liraglutide 3·0 mg group 
had undiagnosed diabetes at withdrawal (based on the 
five additional cases observed in the 12-week off-
treatment follow-up period), whereas we assumed that 
none of those withdrawn in the placebo group did so. We 
secondly assumed that the risk of developing diabetes 
after withdrawal in individuals who did not have diabetes 
at withdrawal (diagnosed or undiagnosed) was the same 
in both treatment groups.
We did five prespecified subgroup analyses to 
investigate whether baseline BMI (four categories) had 
any effect on weight or glycated haemoglobin level 
(appendix p 4). For all statistical analyses in the trial we 
used SAS software, version 9.3. Additional statistical 
analysis details are included in the appendix. The trial is 
registered with ClinicalTrials.gov, number NCT01272219.
Role of the funding source
The funder participated in discussions regarding study 
design and protocol development, and provided logistical 
support during the trial. The funder collected the data, 
and planned and performed the statistical analyses, 
which were assessed by both authors and funder. The 
authors interpreted the data in collaboration with the 
sponsor, and wrote the report together with medical 
writing services provided by the funder. The 
corresponding author had full access to all data and had 
final responsibility for the decision to submit for 
publication.
Results
The study was done between June 1, 2011, and 
March 2, 2015. 2254 individuals with prediabetes, based 
on ADA 2010 criteria,17 were randomised to 3 years of 
lifestyle intervention plus treatment with liraglutide 
Liraglutide 3·0 mg (n=1505) Placebo (n=749)
Sex
Female 1141 (76%) 573 (77%)
Male 364 (24%) 176 (23%)
Age (years) 47·5 (11·7) 47·3 (11·8)
Race*
White 1256 (83%) 628 (84%)
Black or African-American 146 (10%) 71 (9%)
Asian 75 (5%) 39 (5%)
American Indian or Alaska Native 5 (0·3%) 2 (0·3%)
Native Hawaiian or other Pacific Islander 1 (<0·1%) 1 (0·1%)
Other 22 (1·5%) 8 (1·1%)
Hispanic or Latino ethnic group* 143 (10%) 70 (9%)
Weight (kg) 107·5 (21·6) 107·9 (21·8)
BMI (kg/m²) 38·8 (6·4) 39·0 (6·3)
BMI category
27–29·9, overweight 39 (3%) 23 (3%)
30–34·9, obesity class 1 427 (28%) 197 (26%)
35–39·9, obesity class 2 492 (33%) 245 (33%)
≥40, obesity class 3 547 (36%) 284 (38%)
Waist circumference (cm)
Overall 116·5 (14·4) 116·7 (13·9)
Women 113·9 (13·0) 113·8 (12·7)
Men 124·9 (15·0) 126·1 (13·7)
Glycated haemoglobin (%) 5·8 (0·3) 5·7 (0·3)
Fasting glucose (mmol/L) 5·5 (0·6) 5·5 (0·5)
2-h plasma glucose during OGTT (mmol/L) 7·4 (1·8) 7·4 (1·7)
Fasting insulin (pmol/L) 127·6 (76·5) 125·1 (79·1)
Blood pressure (mm Hg)
Systolic 124·7 (12·9) 125·0 (12·8)
Diastolic 79·4 (8·4) 79·8 (8·3)
Cholesterol (mmol/L)
Total 5·0 (19·0) 5·1 (19·0)
LDL cholesterol 2·9 (27·9) 3·0 (28·0)
HDL cholesterol
  Overall 1·3 (26·1) 1·3 (26·4)
  Women (n=1139 vs 572)  1·4 (25·3) 1·4 (25·1)
  Men (n=363 vs 176) 1·1 (22·1) 1·1 (25·1)
VLDL cholesterol 0·7 (46·8) 0·7 (51·3)
Non-HDL cholesterol 3·6 (24·9) 3·7 (25·0)
Free fatty acids (mmol/L) 0·47 (39·6) 0·48 (38·4)
Triglycerides (mmol/L) 1·5 (54·1) 1·5 (66·6)
Dyslipidaemia† 499 (33%) 249 (33%)
Hypertension† 635 (42%) 312 (42%)
Dyslipidaemia and hypertension† 317 (21%) 156 (21%)
Data are observed n (%) or mean (SD). For fasting insulin and lipids, data are geometric means and coefficients of variation. 
BMI=body-mass index. HDL=high-density lipoprotein. LDL=low-density lipoprotein. OGTT=oral glucose-tolerance test. 
VLDL=very low density lipoprotein. *Race and ethnic group were self-reported. Participants from France (44 in all) did not 
report race or ethnic group. †The diagnoses of dyslipidaemia and hypertension were based on reported medical history.
Table 1: Baseline characteristics of all randomised individuals
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Figure 2: Liraglutide 3·0 mg and glycaemic status
LOCF=last-observation-carried-forward. OR=odds ratio. *Derived from the primary Weibull analysis. (A) Kaplan-Meier estimates of the proportion of participants who received a diagnosis of type 2 diabetes 
during the course of the trial. Glycaemic status was defined according to American Diabetes Association 2010 criteria.17 All individuals for whom diabetes was diagnosed had prediabetes at screening, except for 
one in the placebo group, who had normoglycaemia. The numbers along the graph lines show the cumulative number of individuals who received a diagnosis of diabetes over the course of 172 weeks. The time 
until 1% were diagnosed with diabetes was 90 weeks with liraglutide 3·0 mg and 24 weeks with placebo (post-hoc analysis). Participants were off treatment during the 12-week observational follow-up period, 
but still on diet and exercise. (B) Proportion of participants with prediabetes at screening who regressed to having normoglycaemia during the 172 weeks. (C) Changes in fasting plasma glucose and fasting 
serum insulin during the 172 weeks. Changes in fasting glucose translated into a similar corresponding pattern for glycated haemoglobin changes. Changes in HOMA-IR followed a similar pattern as fasting 
insulin changes. Relative changes in fasting glucose (%) are shown in the appendix p 15. Data shown are the observed means with SE (fasting glucose) or with 95% CI (fasting insulin). 
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3·0 mg (n=1505) or placebo (n=749; figure 1). In the 
liraglutide group, 791 (53%) of 1505 participants 
completed 160 weeks of treatment, as did 337 (45%) of 
749 participants in the placebo group. A greater proportion 
of participants in the liraglutide group withdrew owing to 
adverse events (199 [13%] of 1501 participants) than did in 
the placebo group (46 [6%] of 747). A smaller proportion 
of participants in the liraglutide group withdrew owing to 
ineffective therapy (29 [2%] of 1505 participants) than did 
in the placebo group (36 [5%] of 749) or withdrew their 
consent to remain in the trial (324 [22%] of 
1505 participants for liraglutide vs 233 [31%] of 749 for 
placebo). Individuals who withdrew were slightly younger 
than the average trial population; otherwise, we observed 
no noteworthy differences in baseline characteristics or 
medical history (table 1; appendix p 5). The full-analysis 
set comprised 1472 participants in the liraglutide group 
and 738 participants in the placebo group (figure 1).
By week 160, 26 (2%) of 1472 individuals in the 
liraglutide group were diagnosed with diabetes while on 
treatment compared with 46 (6%) of 738 in the placebo 
group. We calculated the cumulative probability of a 
diagnosis of diabetes taking censoring into account: 3% 
of individuals in the liraglutide group were diagnosed 
with diabetes by week 160, compared with 11% in the 
placebo group (figure 2).
For the 26 individuals in the liraglutide group, the 
mean time from randomisation to diagnosis was about 
99 (SD 47) weeks compared with 87 (47) weeks for the 
46 individuals in the placebo group, in a post-hoc 
analysis. Taking the different diagnosis frequencies 
between the treatment groups into account, the time-to-
onset of diabetes over 160 weeks among all randomised 
individuals, while on treatment, was 2·7-times longer 
with liraglutide than with placebo (95% CI 1·9–3·9, 
p<0·0001; appendix p 10), corresponding with a hazard 
ratio (HR) of 0·21 (95% CI 0·13–0·34; p<0·0001).
Results were consistent across sensitivity analyses, and 
the treatment difference remained statistically significant 
after the 12-week off-treatment follow-up period, with 
five additional individuals being diagnosed with diabetes 
with liraglutide, compared with one individual with 
placebo (appendix p 11). We did an additional post-hoc 
analysis at week 172 to address the lack of follow-up 
information for withdrawn participants, and assumed 
that 1% of those withdrawn in the liraglutide group had 
undiagnosed diabetes at withdrawal, whereas none of 
those in the placebo group did (HR 0·34, 95% CI 
0·22–0·53, p<0·0001).
While on treatment, more individuals in the liraglutide 
3·0 mg group (970 [66%] of 1472) had regressed from 
prediabetes to normoglycaemia by week 160 than had 
individuals in the placebo group (268 [36%] of 738; odds 
ratio [OR] 3·6, 95% CI 3·0–4·4, p<0·0001, figure 2), 
corresponding with a number needed to treat of three. 
After a 12-week treatment cessation, some individuals in 
the liraglutide group reverted to prediabetes but 
740 (50%) of 1472 randomised and exposed individuals 
still had normoglycaemia at week 172 compared with 
263 (36%) of 738 of those individuals in the placebo 
group (1·9, 1·6–2·3, p<0·0001).
While on treatment, measures of insulin resistance and 
β-cell function improved in the liraglutide group compared 
with the placebo group at week 160 (appendix p 37), and 
glycated haemoglobin, fasting glucose, and fasting insulin 
concentrations were lower with liraglutide than with 
placebo (table 2). Effects on fasting insulin (figure 2) and 
HOMA-IR (not shown) were sustained after treatment 
cessation from week 160–172; effects on fasting glucose 
(figure 2) and glycated haemoglobin (not shown) were not.
Liraglutide induced greater weight loss than placebo at 
week 160 while on treatment (–6·1% [SD 7·3] for 
Liraglutide 
3·0 mg (n=1472)
Placebo 
(n=738)
Estimated treatment 
difference, liraglutide 
vs placebo (95% CI)*
p value
Change in bodyweight
Percentage of bodyweight –6·1% (7·3) –1·9% (6·3) –4·3 (–4·9 to –3·7) <0·0001
Kg of bodyweight –6·5 (8·1) –2·0 (7·3) –4·6 (–5·3 to –3·9) <0·0001
Loss of ≥5% bodyweight (%)† 49·6% 23·7% 3·2 (2·6 to 3·9) <0·0001
Loss of >10% bodyweight (%)† 24·8% 9·9% 3·1 (2·3 to 4·1) <0·0001
Loss of >15% bodyweight (%)† 11·0% 3·1% 4·0 (2·6 to 6·3) <0·0001
Bodyweight-related endpoints
BMI (kg/m²) –2·4 (2·9) –0·7 (2·6) –1·7 (–1·9 to –1·4) <0·0001
Waist circumference (cm) –6·9 (8·3) –3·4 (7·5) –3·5 (–4·2 to –2·8) <0·0001
Women (n=1110 vs 565) –7·2 (8·3) –3·1 (7·3) –4·0 (–4·8 to –3·2) <0·0001
Men (n=362 vs 173) –5·9 (8·1) –4·3 (8·0) –1·9 (–3·4 to –0·5) 0·0080
Glycaemic control parameters
Glycated haemoglobin (% points) –0·35 (0·32) –0·14 (0·34) -0·21 (–0·24 to –0·18) <0·0001
Fasting glucose (mmol/L) –0·37 (0·68) 0·05 (0·62) –0·41 (–0·46 to –0·36) <0·0001
Fasting insulin (%) –8·3% 1·7% –10·1 (–14·3 to –5·6) <0·0001
Fasting C-peptide (%) –4·1% –3·2% –1·3 (–4·4 to 2·0) 0·44
PG AUC during OGTT (h*mmol/L) –2·5 (6·3) –0·16 (7·2) –2·4 (–3·0 to –1·8) <0·0001
Insulin AUC during OGTT (%) –0·3 –11·4 11·0 (4·8 to 17·7) 0·0004
C-peptide AUC during OGTT (%) –1·7 –10·2 8·8 (4·5 to 13·4) <0·0001
2-h PG during OGTT (mmol/L) –1·6 (2·1) –0·2 (2·2) –1·4 (–1·6 to –1·3) <0·0001
Vital signs
Systolic blood pressure (mm Hg) –3·2 (13·0) –0·5 (13·7) –2·8 (–3·8 to –1·8) <0·0001
Diastolic blood pressure (mm Hg) –2·3 (9·0) –1·9 (9·3) –0·6 (–1·3 to 0·1) 0·09
Heart rate (beats per min) 2·1 (10·0) –0·02 (9·8) 2·0 (1·2 to 2·7) <0·0001
Data are observed means (SD), unless otherwise stated, using available data from the full-analysis set, with LOCF 
imputation. For insulin and C-peptide, data were log-transformed for analysis and presented as the relative changes from 
baseline and relative treatment differences. Post-hoc analysis was performed for weight loss greater than 15%. Changes 
from baseline to week 172, after a 12-week observational follow-up period, are presented in the appendix p 38. 
BMI=body-mass index. AUC=area under the curve. LOCF=last-observation-carried-forward. OGTT=oral glucose-tolerance 
test. PG=plasma glucose. *Estimated treatment differences for all endpoints, except heart rate, are from an analysis of 
covariance with available data from the full-analysis set, with LOCF imputation. The full-analysis set comprised 
individuals who underwent randomisation, were exposed to at least one treatment dose, and had at least 
one assessment after randomisation (44 individuals were excluded from the full-analysis set: 38 due to lack of an 
assessment and 6 due to no exposure). Data for heart rate are based on the safety-analysis set, which included all 
individuals who underwent randomisation and were exposed to at least one treatment dose. †Loss of at least 5%, 
more than 10%, and more than 15% (post-hoc)  of bodyweight were analysed by logistic regression with data from the 
full-analysis set (n=1467 in the liraglutide group and n=734 in the placebo group), with LOCF imputation, and are 
presented as the proportions of participants (%) and odds ratios. 
Table 2: Changes in bodyweight and cardiometabolic risk factors between baseline and week 160
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liraglutide vs –1·9% [6·3] for placebo; estimated 
treatment difference –4·3%, 95% CI –4·9 to –3·7, 
p<0·0001). Weight loss with liraglutide treatment was 
sustained over 3 years (figure 3). Greater mean and 
categorical weight loss were achieved in the liraglutide 
group than in the placebo group (table 2, figure 3). After 
treatment cessation at week 160, some weight was 
regained in the liraglutide group, although the treatment 
difference was still significant at week 172 (–3·2%, 
95% CI –4·3 to –2·2, p<0·0001; appendix p 38).
All prespecified sensitivity analyses confirmed the 
superiority of liraglutide over placebo on mean weight 
loss (appendix p 37). Treatment effects for weight-related 
endpoints and glycated haemoglobin were consistent 
across BMI subgroups (appendix p 18).
More than 90% of individuals in each treatment group 
who were diagnosed with diabetes lost less bodyweight 
than the treatment group mean at the time of diagnosis 
(appendix p 20).
Systolic blood pressure was statistically significantly 
decreased with liraglutide compared with placebo at 
week 160 while on treatment; diastolic blood pressure 
was not (table 2). Effects on fasting lipids and 
cardiovascular biomarkers were generally modest 
(appendix p 39), but levels of high-sensitivity C-reactive 
protein were substantially lower with liraglutide than 
with placebo (–36·9% vs –11·0%; estimated treatment 
difference, –29%, 95% CI –34 to –23, p<0·0001).
Liraglutide 3·0 mg was associated with higher mean 
scores on the SF-36 physical component summary score 
and the Impact of Weight on Quality of Life–Lite total 
score, indicating improved health-related quality of life 
compared with placebo (appendix p 39).
Gastrointestinal disorders, 93% of which were mild or 
moderate in severity, were the most common side-effects 
in the liraglutide 3·0 mg group (table 3), and also the most 
common cause of withdrawal (118 [8%] of 1501 individuals 
in the liraglutide group vs 11 [2%] of 747 in the placebo 
group; adverse events leading to discontinuation of 
≥0·2% individuals in either group are in the appendix 
p 23). More serious adverse events were reported in the 
liraglutide group than in the placebo group (table 3). 
Figure 3: Liraglutide 3·0 mg and bodyweight
Data shown are the observed means for the full-analysis set, with LOCF. LOCF=last-observation-carried-forward. OR=odds ratio. *p<0·0001. †Analysis for >15% weight 
loss was done post hoc. (A) Mean relative change in bodyweight for individuals in the full-analysis set who completed each scheduled visit. Data shown are the 
observed means with SE. (B) The proportion of participants who lost at least 5%, more than 10%, and more than 15% of their baseline bodyweight at week 160. 
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Adverse event incidence generally declined during the trial 
(appendix p 25). Four individuals died—two in the 
liraglutide group (due to cardiac arrest and metastatic 
cholangiocarcinoma) and two in the placebo group 
(pulmonary failure and cancer, primary tumour unknown).
As previously reported,11 gallbladder-related events 
were more common with liraglutide than with placebo 
(occurring in 74 [5%] of 1501 individuals for liraglutide vs 
13 of [2%] 747 individuals for placebo and 2·9 events per 
100 person-years of observation [PYO] for liraglutide and 
1·2 events per 100 PYO for placebo). More cases of 
cholelithiasis and cholecystitis occurred at relatively 
constant rates over 3 years in the liraglutide group. 
Weight loss among individuals with gallbladder-related 
events in the liraglutide group was generally greater than 
the treatment group mean (appendix p 28).
Pancreatitis and neoplasms were assessed over 
172 weeks (appendix p 5). Overall, 12 pancreatitis cases 
(eleven graded as mild, one as moderately severe),22 were 
confirmed by adjudication, occurring in ten (0·7%) of 
1501 individuals in the liraglutide group (0·3 events per 
100 PYO), and in two (0·3%) of 747 placebo-group 
individuals (0·1 events per 100 PYO). Eight events in the 
liraglutide group occurred in the first year (appendix 
p 26). Five individuals (four in the liraglutide group) had 
gallstone-related pancreatitis, with liver enzyme 
concentrations at least 3 times the upper limit of the 
normal range or gallstones on imaging (appendix p 41).23
The incidence of adjudicated and confirmed neoplasms 
was similar in both treatment groups (2·2 events per 
100 PYO for liraglutide vs 2·4 for placebo). As seen in the 
56-week period of the trial,11 more cases of malignant and 
premalignant breast neoplasms were reported with 
liraglutide: ten malignant and pre-malignant breast 
neoplasms were observed in nine women in the liraglutide 
group, seven occurring in the first year, and no events in 
the placebo group (appendix p 27). Most women with 
neoplasms had above-average weight loss (appendix p 42). 
We observed no cases of medullary thyroid carcinoma or 
C-cell hyperplasia. Liraglutide treatment did not increase 
median serum calcitonin concentrations.
Resting heart rate increased in the liraglutide group at 
week 160 by about 2 beats per min (table 2). Increases of 
more than 5, 10, and 20 beats per min on at least 
two consecutive visits are shown in the appendix p 42. 
Prespecified cardiovascular events (appendix p 33) 
occurred in 242 (16%) of 1501 individuals in the liraglutide 
group (12·1 events per 100 PYO) compared with 142 (19%) 
of 747 individuals in the placebo group (15·1 events per 
100 PYO). The incidence of adjudication-confirmed major 
adverse cardiovascular events (cardiovascular death, non-
fatal myocardial infarction, non-fatal stroke) was similarly 
low in both treatment groups (0·19 events per 100 PYO 
for liraglutide vs 0·20 for placebo).
We observed no between-group differences for 
psychiatric disorders, or questionnaire-based depression, 
or suicidal behaviour scores. However, seven individuals 
treated with liraglutide (vs none treated with placebo) 
reported eight suicidal ideation events and one individual 
in the placebo group (vs none in the liraglutide group) 
reported suicidal depression. One suicide attempt 
occurred in each group (appendix p 6).
Results from the 12-week observational follow-up 
period and additional safety information, including 
results on hypoglycaemia, anti-liraglutide antibodies, 
and pregnancies, are provided in the appendix.
Discussion
In individuals with overweight or obesity and prediabetes, 
3 years of continued treatment with once-daily liraglutide 
3·0 mg, as an adjunct to diet and exercise, was associated 
Liraglutide 3·0 mg (n=1501) Placebo (n=747)
Participants 
n (%)
Events
(n)
Event rate per 
100 years of 
observation
Participants 
n (%)
Events
(n)
Event rate per 
100 years of 
observation
Total number of 
adverse events
1421 (95%) 15 759 489·6 668 (89%) 6350 431·9
Adverse events in 
≥5% of individuals
1322 (88%) 8240 256·0 579 (78%) 2837 193·0
Gastrointestinal disorders
Nausea 614 (41%) 961 29·9 125 (17%) 166 11·3
Diarrhoea 379 (25%) 610 19·0 107 (14%) 145 9·9
Constipation 331 (22%) 419 13·0 85 (11%) 100 6·8
Vomiting 295 (20%) 472 14·7 40 (5%) 53 3·6
Dyspepsia 154 (10%) 192 6·0 35 (5%) 40 2·7
Abdominal pain 114 (8%) 152 4·7 38 (5%) 50 3·4
Upper abdominal 
pain
112 (8%) 139 4·3 39 (5%) 47 3·2
Gastro-oesophageal 
reflux disease
98 (7%) 110 3·4 18 (2%) 20 1·4
Eructation 85 (6%) 95 3·0 4 (<1%) 4 0·3
Flatulence 81 (5%) 94 2·9 20 (3%) 23 1·6
General disorders and administration site conditions
Fatigue 152 (10%) 188 5·8 57 (8%) 66 4·5
Injection site 
haematoma
91 (6%) 102 3·2 60 (8%) 68 4·6
Oedema peripheral 53 (4%) 60 1·9 47 (6%) 58 3·9
Infections and infestations
Nasopharyngitis 396 (26%) 755 23·5 209 (28%) 405 27·5
Upper respiratory 
tract infection
235 (16%) 388 12·1 119 (16%) 212 14·4
Influenza 181 (12%) 252 7·8 79 (11%) 122 8·3
Gastroenteritis 142 (9%) 173 5·4 46 (6%) 53 3·6
Sinusitis 128 (9%) 173 5·4 65 (9%) 111 7·6
Urinary tract 
infection
121 (8%) 176 5·5 43 (6%) 62 4·2
Bronchitis 114 (8%) 139 4·3 62 (8%) 82 5·6
Investigations
Lipase increased 146 (10%) 208 6·5 23 (3%) 25 1·7
Metabolism and nutrition disorders
Decreased appetite 164 (11%) 176 5·5 26 (4%) 27 1·8
(Table 3 continues on next page)
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with lower risk of a type 2 diabetes diagnosis and greater 
sustained weight loss compared with placebo. Generally, 
lifestyle intervention can reduce relative risk of diabetes by 
40–70%, and enhance insulin sensitivity and β-cell 
function in individuals with prediabetes at high-risk of 
developing type 2 diabetes.4 In both the Diabetes 
Prevention Program (DPP)6 and Finnish Diabetes 
Prevention Study (DPS),7 lifestyle intervention compared 
with placebo was associated with a 58% reduction in the 
risk of diabetes after 3 years. Furthermore, the DPP 
showed that metformin treatment was associated with a 
31% risk reduction compared with placebo.6 In a 
pharmacotherapy trial in individuals with obesity, 4 years 
of treatment with orlistat was associated with a 
37% reduced risk of diabetes, concomitant with a mean 
5·8 kg weight loss compared with 3·0 kg with placebo.8 
Additionally, 2 years of treatment with phentermine/
topiramate provided a reduction versus placebo in the 
annualised incident rate of type 2 diabetes of 71% or 79%, 
depending on the dose, in individuals with prediabetes, or 
metabolic syndrome, or both.9 Mean weight loss was 
10·9% and 12·1% for the two phentermine/topiramate 
doses versus 2·5% with placebo. Pioglitazone reduced the 
conversion of impaired glucose tolerance to type 2 diabetes 
by 72% compared with placebo after a median follow-up 
period of 2·4 years, although it was associated with 
significant weight gain.24 In this study, we address both 
weight-loss mediated and direct glucose-dependent 
insulinotropic effects of liraglutide 3·0 mg on the 
progression to type 2 diabetes. Liraglutide was associated 
with a risk reduction of about 80% relative to placebo 
(HR 0·21, 95% CI 0·13–0·34) in the onset of type 2 
diabetes. However, our primary analysis did not take into 
account the lack of follow-up information for withdrawn 
individuals. Therefore, we did a post-hoc analysis that 
made assumptions about those withdrawn individuals, 
which provided a risk reduction of about 66% relative to 
placebo (HR 0·34, 95% CI 0·22–0·53).
Whether the lack of a response to treatment for some 
individuals in the current trial was a result of individual 
participant characteristics, or due to other factors, is 
unclear. Most individuals who were diagnosed with 
diabetes lost less bodyweight than the treatment group 
mean at the time of diagnosis.
Regression from prediabetes to normoglycaemia was 
observed in 66% of individuals in the liraglutide group 
while on treatment for 160 weeks, and was associated 
with a lower risk of diabetes.5 Similar results have been 
observed previously with liraglutide and other GLP-1 
receptor agonists.11,25–27 The combination of weight loss 
and glycaemic improvements achieved with liraglutide 
and lifestyle intervention likely contributed to the greater 
regression to normoglycaemia and longer time to onset 
of diabetes observed. Furthermore, findings from the 
DPP Outcomes Study show that regression to 
normoglycaemia by any means is associated with a 
56% lower risk of diabetes.5,28 Collectively, these results 
support the beneficial use of pharmacotherapy to lower 
the risk of diabetes with the potential to reduce 
cardiovascular risk factors in individuals with obesity and 
prediabetes.4
Compared with the DPP, which recruited individuals 
with impaired fasting glucose and impaired glucose 
tolerance, we enrolled a lower-risk, less progressed 
population because we allowed for fulfilment of any one 
of three ADA 2010 diagnostic criteria17 at enrolment. 
This difference, together with the weight loss achieved, 
might partly explain the lower diabetes incidence of 
11% observed in our lifestyle placebo group, compared 
with the cumulative incidence of 14·4% at 3 years seen in 
the DPP for the lifestyle intervention group and 28·9% in 
the placebo group.6
The improvements previously observed11 in bodyweight, 
glycaemia and cardiometabolic risk factors were generally 
sustained over 3 years. Similar improvements in many of 
these parameters, such as high-sensitivity C-reactive 
protein, have been observed with several GLP-1 receptor 
Liraglutide 3·0 mg (n=1501) Placebo (n=747)
Participants 
n (%)
Events 
(n)
Event rate per 
100 years of 
observation
Participants 
n (%)
Events 
(n)
Event rate per 
100 years of 
observation
(Continued from previous page)
Musculoskeletal and connective tissue disorders
Back pain 200 (13%) 287 8·9 120 (16%) 162 11·0
Arthralgia 184 (12%) 229 7·1 97 (13%) 135 9·2
Pain in extremity 108 (7%) 127 3·9 54 (7%) 64 4·4
Nervous system disorders
Headache 270 (18%) 427 13·3 122 (16%) 219 14·9
Dizziness 146 (10%) 195 6·1 54 (7%) 72 4·9
Respiratory, thoracic, and mediastinal disorders
Cough 111 (7%) 132 4·1 59 (8%) 85 5·8
Oropharyngeal pain 74 (5%) 81 2·5 44 (6%) 52 3·5
Vascular disorders
Hypertension 75 (5%) 87 2·7 47 (6%) 57 3·9
Total number of 
serious adverse events
227 (15%) 350 10·9 96 (13%) 143 9·7
Serious adverse events in ≥0·4% of individuals
Cholelithiasis 20 (1%) 21 0·7 6 (1%) 6 0·4
Cholecystitis acute 9 (1%) 9 0·3 1 (<1%) 1 <0·1
Cholecystitis 6 (<1%) 6 0·2 0 0 0
Osteoarthritis 12 (1%) 14 0·4 5 (1%) 6 0·4
Intervertebral disc 
protrusion
6 (<1%) 6 0·2 1 (<1%) 1 <0·1
Back pain 4 (<1%) 4 0·1 3 (<1%) 3 0·2
Fall 0 0 0 4 (1%) 4 0·3
Cellulitis 3 (<1%) 3 0·1 3 (<1%) 3 0·2
Obesity 1 (<1%) 1 <0·1 3 (<1%) 3 0·2
Adverse events (grouped by their system organ class) and serious adverse events that occurred up to and including 
week 162 among individuals in the safety-analysis set are included and are presented by their preferred terms from the 
Medical Dictionary for Regulatory Activities. Events are included if they had an onset date on or after the first day that 
the study drug was administered and no later than 14 days after the last day the study drug was administered.
Table 3: Adverse events and serious adverse events
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agonists,29,30 including liraglutide.12–14 After 12 weeks of 
treatment cessation, effects on glycated haemoglobin 
and fasting glucose disappeared with liraglutide, whereas 
fasting insulin remained low and unchanged, supporting 
differential (direct vs indirect) effects of liraglutide on 
glucose metabolism and diabetes risk. Because the 
participants lost more weight with liraglutide than 
placebo, future studies should quantify the relative 
contributions of weight loss versus the direct effects of 
liraglutide on glucose homoeostasis with respect to 
diabetes risk reduction.
The safety profile over 3 years was in line with that 
observed over the initial 56-week period.11 The numerical 
imbalance in gallbladder-related events, including chole-
lithiasis and cholecystitis events that occurred at relatively 
constant rates during the 3 years in the liraglutide group, 
is under investigation. Obesity and weight loss are both 
associated with an increased risk of gallstone formation.31 
Greater weight loss was generally observed among 
individuals in the liraglutide group who reported 
gallbladder-related events compared with the overall 
liraglutide population mean. The cause of the greater 
number of breast neoplasms in the liraglutide group, 
70% of which occurred during the first year, is still unclear, 
but weight loss could have increased detection. The 
underlying mechanism for the increased resting heart 
rate with liraglutide is also unknown; a direct chronotropic 
effect of liraglutide on the sinoatrial node has been 
suggested.32
The prevalence of obesity and type 2 diabetes and their 
associated major comorbidities and health-care costs 
highlight the need for effective treatments. Adverse events 
in our trial were mostly predictable on the basis of the 
known effects of GLP-1 receptor agonists, including more 
gastrointestinal disorders with liraglutide than with 
placebo, notably nausea, diarrhoea, constipation, and 
vomiting. The increased heart rate associated with 
liraglutide, as observed with other GLP-1 receptor agonists, 
did not lead to an increased cardiovascular risk in a large 
cardiovascular-outcomes trial with liraglutide doses up to 
1·8 mg.33 Generally, liraglutide has a well-documented 
safety profile.11–14,26,33 Although the frequencies of 
gallbladder-related events and pancreatitis were greater in 
the liraglutide group than in the placebo group, the 
incidence of both was relatively low and will be monitored 
regularly in the post-marketing setting by routine 
pharmaco vigilance. Overall, the long-term efficacy and 
safety results for this trial indicate that the benefits of 
treatment with liraglutide 3·0 mg outweigh the risks in 
this already at-risk population of individuals with obesity 
or overweight with comorbidities. Data we provide in this 
trial will enable clinicians to attenuate the risks of 
individuals while optimising the benefits.
Although the 3-year retention rate of 53% in the 
liraglutide group and 45% in the placebo group is 
comparable with another long-term obesity trial,8 the 
missing data due to participant withdrawal is a limitation 
when interpreting the primary endpoint and reported 
adverse events. However, a post-hoc analysis accounting 
for the lack of follow-up information showed that the risk 
of diabetes was about 66% lower with liraglutide 
compared with placebo, the magnitude of which 
compares with the 58% lower risk observed in the DPP6 
and DPP Outcomes Study,28 with higher retention and 
longer follow-up.
3 years of treatment with once-daily subcutaneous 
liraglutide 3·0 mg, as an adjunct to a reduced-calorie diet 
and increased physical activity, reduced the risk of type 2 
diabetes in individuals with overweight or obesity and 
prediabetes, and promoted greater weight loss and 
improvements in glycaemic control and cardiometabolic 
risk factors compared with placebo. Liraglutide 3·0 mg, 
as a GLP-1 receptor agonist, provides a different 
treatment option for individuals with obesity or 
overweight, with or without type 2 diabetes, having direct 
glucose-dependent effects on insulin secretion and 
weight-loss mediated effects on improved insulin 
resistance. Liraglutide 3·0 mg was generally well 
tolerated. However, post-market surveillance will be 
exercised to ensure detection of potential side-effects 
with a very low incidence.
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